Non-cell-Autonomous Cardiomyocyte Regulation Complicates Gene Supplementation Therapy for Lmna-Associated Cardiac Defects in Mice
简介:
- 作者: Yueshen Sun, Congting Guo, Zhan Chen, Junsen Lin, Luzi Yang, Yueyang Zhang, Chenyang Wu, Dongyu Zhao, Blake Jardin, William T. Pu, Mingming Zhao, Erdan Dong, Xiaomin Hu, Shuyang Zhang, Yuxuan Guo
- 杂志: JACC-Basic to Translational Science
- Doi: https://www.doi.org/10.1016/j.jacbts.2024.06.004
- 出版日期: 2024 Aug 21
论文中使用的产品/服务
Quotation shows PackGene:AAV production was performed in house or at PackGene Biotech. We produced AAV9 as previously described.
Research Field:Lmna-Associated Cardiac Defects
AAV Serotype:AAV9
Targeted organ:liver, heart, skeletal muscles
Animal or cell line strain:mice
摘要
The truncating mutations of LMNA are the major causes of cardiomyopathy. Here we studied 3 mouse models that carry germline, cardiomyocyte-specific, or genetic mosaic Lmna truncating mutations. Whereas the germline mutant manifested cardiac maturation defects, cardiomyocyte-specific mutation triggered pathological hypertrophy. In genetic mosaic analysis, no morphological defects were observed. Three adeno-associated virus (AAV) vectors were applied to addback lamin-A in a ubiquitous, cardiomyocyte-specific, or cardiomyocyte-excluded manner. Strikingly, only ubiquitous and cardiomyocyte-excluded AAV vectors mitigated the cardiac defects. Therefore, Lmna regulates cardiac morphology and function via a non-cell-autonomous mechanism. Noncardiomyocytes are key targets in AAV lamin-A therapy for Lmna-associated cardiac defects.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。